{"gene":"PAPPA","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":1999,"finding":"PAPP-A was identified as the IGF-dependent IGFBP-4 protease activity present in conditioned media from human fibroblasts; it cleaves IGFBP-4 only when IGF is bound to IGFBP-4, releasing bioactive IGF.","method":"Biochemical purification and protease activity assay from human fibroblast conditioned media","journal":"Growth hormone & IGF research","confidence":"High","confidence_rationale":"Tier 1 / Strong — foundational biochemical purification and enzymatic characterization, independently replicated and widely accepted as the defining function of PAPP-A","pmids":["17218136"],"is_preprint":false},{"year":1979,"finding":"PAPP-A was purified and characterized as an alpha-2 glycoprotein of ~750–820 kDa, likely a dimer composed of two polypeptide chains of ~218 kDa each; in vitro it inhibited complement activity, caseinolytic activity of plasmin, and thrombin-induced coagulation via activation of antithrombin III.","method":"Protein purification (ammonium sulfate precipitation, ion-exchange, affinity chromatography, gel filtration); in vitro complement, plasmin, and coagulation inhibition assays","journal":"Archives of gynecology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct biochemical characterization in a single early study; functional roles in coagulation/complement not widely corroborated in later work","pmids":["518134"],"is_preprint":false},{"year":1983,"finding":"Purified PAPP-A inhibits thrombin-induced coagulation of plasma by activating endogenous antithrombin III (not by direct inhibition of thrombin); this inhibitory effect is neutralized by protamine sulfate, suggesting PAPP-A carries strongly acidic (heparin-like) residues.","method":"In vitro coagulation assay with purified PAPP-A, euglobulin system, antithrombin III titration, protamine sulfate neutralization","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro biochemical assay with mechanistic dissection, single laboratory","pmids":["6197764"],"is_preprint":false},{"year":2007,"finding":"PAPP-A is a metzincin metalloproteinase that cleaves IGFBP-4 (and IGFBP-2 and IGFBP-5) in an IGF-dependent manner; it is cell surface-associated via tight binding to glycosaminoglycans, positioning it to increase local IGF bioavailability for IGF receptor activation.","method":"Review of biochemical assays, cell-surface binding experiments, and PAPP-A knockout mouse studies","journal":"Growth hormone & IGF research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods across multiple laboratories establish IGFBP protease activity, cell-surface binding, and in vivo IGF regulation","pmids":["17218136","25617049"],"is_preprint":false},{"year":2010,"finding":"PAPP-A knockout (KO) female mice show complete loss of ovarian IGFBP-4 proteolytic activity, reduced ovulated oocyte numbers, lower estradiol and progesterone levels, and reduced steroidogenic enzyme gene expression, demonstrating that PAPP-A-mediated IGFBP-4 cleavage is required for normal ovarian steroidogenesis and female fertility.","method":"Pappa gene-targeted knockout mouse; IGFBP-4 proteolytic activity assay in follicular fluid; serum hormone measurement; ovarian gene expression analysis","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO with multiple orthogonal phenotypic readouts (activity assay, hormone levels, gene expression) in a single well-characterized genetic model","pmids":["20130263"],"is_preprint":false},{"year":2014,"finding":"An inhibitory monoclonal antibody (mAb 1/41) targeting a substrate-binding exosite of PAPP-A selectively inhibits IGFBP-4 cleavage (Ki = 135 pM), suppresses IGF receptor (AKT) signaling in lung cancer cells, and inhibits tumor growth in a murine A549 xenograft model, establishing that PAPP-A's proteolytic activity toward IGFBP-4 is required for pericellular IGF signaling.","method":"Inhibitory monoclonal antibody development; in vitro IGFBP-4 cleavage assay; AKT phosphorylation assay in cell monolayers; murine xenograft tumor model; tumor tissue immunohistochemistry","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — exosite-targeting antibody with defined Ki, in vitro signaling assay, and in vivo xenograft validation in single lab with multiple orthogonal readouts","pmids":["24572990"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structure of the 500 kDa 2:2 PAPP-A·stanniocalcin-2 (STC2) complex (3.1 Å for the STC2 and N-terminal ~1000 residues of PAPP-A) revealed that STC2 inhibits PAPP-A via: (1) a specific intermolecular disulfide bond preventing dissociation, and (2) interactions between STC2 and the very C-terminal module of PAPP-A that sterically prevent IGFBP-4 binding; the catalytic active site remains accessible to synthetic peptides, establishing an unusual substrate-exclusion mechanism of inhibition.","method":"Single-particle cryo-electron microscopy (cryo-EM); synthetic peptide hydrolysis assay; biochemical characterization of PAPP-A·STC2 complex","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structure with biochemical validation of inhibitory mechanism, published in peer-reviewed journal","pmids":["36257932"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structures of catalytically inactive PAPP-A(E483A) alone and in complex with an IGFBP5 peptide revealed that PAPP-A is a flexible trans-dimer that binds IGFBP5 via a unique 25-amino acid anchor peptide extending into the metalloprotease active site; the central domain of PAPP-A mediates both IGFBP5 recognition and trans-dimerization; trans-dimer formation and distal inter-domain interactions are required for efficient proteolysis of IGFBP4 but dispensable for IGFBP5 cleavage.","method":"Single-particle cryo-EM; AlphaFold-assisted model building; active-site mutant (E483A); biochemical proteolysis assays with IGFBP4 and IGFBP5","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure with mutagenesis and in vitro cleavage assays in a single rigorous study","pmids":["36127359"],"is_preprint":false},{"year":2013,"finding":"In zebrafish, knockdown of papp-a slows developmental rate beginning at gastrulation; this phenotype is rescued by proteolytically inactive Papp-a mRNA as efficiently as wild-type, demonstrating that Papp-a has a biologically important function independent of its IGFBP proteolytic activity.","method":"Zebrafish morpholino knockdown; rescue with wild-type vs. proteolytically inactive (active-site mutant) Papp-a mRNA; in vitro recombinant proteolytic activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — genetic knockdown with rescue by catalytic mutant, supported by biochemical confirmation of activity loss, demonstrating non-proteolytic function","pmids":["23430244"],"is_preprint":false},{"year":2019,"finding":"PAPP-A is expressed on the cell surface of Ewing sarcoma (EWS) cells; CRISPR/Cas9 knockout of PAPPA revealed an essential survival role through local IGF-1 bioavailability regulation; PAPPA knockout also induced interferon-response genes involved in antigen processing/presentation, linking PAPP-A to immune evasion in EWS.","method":"CRISPR/Cas9 knockout; anti-PAPP-A antibody treatment; NSG xenograft orthotopic tumor model; RNA-sequencing on PAPPA-KO vs. control EWS clones","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with RNA-seq and in vivo xenograft model, multiple orthogonal readouts in single rigorous study","pmids":["30698726"],"is_preprint":false},{"year":2020,"finding":"PAPPA regulates maternal adipose tissue remodeling in pregnancy through IGF bioavailability; recombinant PAPPA stimulates ex vivo human adipose tissue expansion in an IGFBP-5- and IGF-1-dependent manner; Pappa-KO mice show impaired adipose remodeling, pregnancy-induced insulin resistance, and hepatic steatosis, phenocopying aspects of gestational diabetes.","method":"Pappa knockout mouse model; ex vivo human adipose tissue expansion assay with recombinant PAPPA; IGFBP-5 and IGF-1R neutralization to confirm pathway dependence; clinical cohort correlation","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse with multiple metabolic phenotypes plus ex vivo mechanistic assay with pathway-specific inhibitors, single study with orthogonal methods","pmids":["33239385"],"is_preprint":false},{"year":2020,"finding":"PAPP-A transcription in polycystic kidney disease (ADPKD) is regulated through the cAMP/CREB/CBP/p300 pathway; PAPP-A deficiency inhibits cyst development in Pkd1RC/RC mice; treatment with an anti-PAPP-A monoclonal antibody blocking IGFBP4 proteolysis ameliorates cystic disease in vivo and ex vivo in embryonic kidneys, establishing PAPP-A/IGF-1 signaling as a driver of cyst growth.","method":"Pappa knockout in Pkd1RC/RC mouse model; cAMP/CREB pathway inhibitor experiments; monoclonal antibody treatment (mAb targeting IGFBP4-proteolysis exosite) in vivo and in embryonic kidney cultures; histopathology","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological antibody approach with defined mechanism, multiple in vivo and ex vivo readouts in single lab","pmids":["31990681"],"is_preprint":false},{"year":2012,"finding":"PAPP-A decreases expression of ABCA1, ABCG1, and SR-B1 and reduces cholesterol efflux in THP-1 macrophage-derived foam cells by activating the IGF-1/PI3K/Akt signaling pathway, which downregulates LXRα; PI3K inhibitors or IGF-1R siRNA (but not MAPK inhibitors) rescued the effect.","method":"PAPP-A protein treatment of THP-1 macrophage-derived foam cells; PI3K inhibitors; IGF-1R siRNA knockdown; LXRα agonist rescue experiment; RT-PCR and Western blot for ABCA1/ABCG1/SR-B1/LXRα; cholesterol efflux assay","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors and siRNA with orthogonal endpoints in a single lab study","pmids":["22503545"],"is_preprint":false},{"year":2003,"finding":"PAPP-A expression and secretion are strongly upregulated during in vitro differentiation of villous cytotrophoblasts into syncytiotrophoblasts (~19-fold increase in mRNA, ~8-fold increase in secretion), independent of gestational age.","method":"Primary human villous cytotrophoblast culture; real-time PCR; immunocytochemistry; TRACE immunoassay for secreted PAPP-A","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct functional localization and expression linked to trophoblast differentiation, single lab study","pmids":["12744930"],"is_preprint":false},{"year":2006,"finding":"PPARγ activation inhibits PAPP-A gene expression and secretion in invasive extravillous cytotrophoblasts (EVCT) but not in villous cytotrophoblasts (VCT); since PPARγ agonist inhibits EVCT invasion, PPARγ-mediated downregulation of PAPP-A may reduce bioactive IGF-II and thereby decrease trophoblast invasion.","method":"Primary EVCT and VCT cultures isolated from first-trimester chorionic villi; PPARγ agonist treatment; PAPP-A gene expression (RT-PCR) and secretion assay","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct pharmacological intervention with transcriptional and secretion readouts, single lab, mechanistic link to invasion proposed but not directly tested","pmids":["16388849"],"is_preprint":false},{"year":2013,"finding":"PAPP-A-deficient mice show resistance to indicators of diabetic nephropathy (Bowman's capsule thickening, increased glomerular size, mesangial expansion, macrophage infiltration) despite equivalent hyperglycemia compared with wild-type diabetic mice, establishing a pathogenic role of PAPP-A in diabetic kidney disease.","method":"Pappa KO mouse; streptozotocin-induced diabetes; renal histopathology; immunohistochemistry for macrophage markers","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean genetic KO with defined histological phenotype, single lab","pmids":["23881937"],"is_preprint":false},{"year":2016,"finding":"In PAPP-A KO mice, mTORC1 activity is diminished and MGMT and NDRG1 (DNA repair proteins) are upregulated via post-transcriptional mechanisms; this upregulation is linked to alterations in the CCR4-NOT complex downstream of mTORC1, connecting PAPP-A deficiency to enhanced DNA damage repair and longevity.","method":"PAPP-A KO mouse; mTORC1 activity assay; Western blot for MGMT and NDRG1; CCR4-NOT complex analysis; post-transcriptional regulation assays","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic KO with pathway analysis and post-transcriptional mechanism, single lab, compared across three long-lived mutant models","pmids":["27618784"],"is_preprint":false},{"year":2019,"finding":"The common SNP rs7020782 (serine variant) in PAPPA encodes a PAPP-A protein with significantly reduced proteolytic cleavage of IGFBP-4 compared to the tyrosine variant; no differences were found in cell-surface binding, complex formation with STC2 or proMBP, or STC1 inhibition, localizing the functional impact to IGFBP-4 proteolytic activity specifically.","method":"Recombinant PAPP-A variants expressed in HEK293T cells; IGFBP-4, IGFBP-2, IGFBP-5 cleavage assays; cell-surface binding assay; co-immunoprecipitation with STC2 and proMBP","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — in vitro recombinant protein assay with multiple substrates and controls, single lab","pmids":["31519945"],"is_preprint":false},{"year":2021,"finding":"PAPP-A inhibition (neutralizing antibody) reduces IGF signaling and ECM gene expression system-wide in adult mice; mesenchymal stromal cells (MSCs) in bone marrow are identified as the primary source of PAPP-A and the primary responders, with reduced MSC number and IGF signaling accounting for decreased bone, marrow adiposity, and myelopoiesis; MSC-like cells are also the major PAPP-A source in other tissues.","method":"PAPP-A neutralizing antibody treatment in adult mice; transcriptomic profiling across tissues; bone marrow fractionation; immunohistochemistry; IGF signaling assays","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological antibody with transcriptomic and cell-type-specific mechanistic readouts, single lab","pmids":["33561324"],"is_preprint":false},{"year":2019,"finding":"PAPP-A activates the collagen receptor DDR2 and promotes metastasis in post-partum mammary glands; CRISPR deletion of DDR2 abolished the pro-invasive effect of PAPP-A, establishing DDR2 as a required downstream effector; PAPP-A also converts anti-proliferative post-partum collagen into pro-tumorigenic collagen architecture.","method":"PAPP-A transgenic/KO mouse model; second-harmonic generation microscopy for collagen architecture; CRISPR/Cas9 DDR2 knockout; invasion assay; transcriptomic analysis","journal":"Breast cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR epistasis with invasion assay and structural collagen analysis, multiple orthogonal methods in single lab","pmids":["31046834"],"is_preprint":false},{"year":2022,"finding":"In human lung fibroblasts (NHLF), TGF-β treatment increases PAPP-A levels and proteolytic activity in conditioned medium ~4-fold and stimulates IGF-I expression; the resulting PI3K/Akt signaling is significantly inhibited by both IGF-I-inactivating and PAPP-A inhibitory antibodies; senescent NHLF secrete 10-fold more PAPP-A with increased proteolytic activity, and active PAPP-A is also present on secreted extracellular vesicles.","method":"Primary NHLF cultures; TGF-β treatment; PAPP-A activity assay; PI3K/Akt phosphorylation assay; IGF-I and PAPP-A inhibitory antibodies; senescence induction; extracellular vesicle isolation and characterization","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (activity assay, signaling, EV characterization) with pathway-specific inhibitors in primary human cells, single lab","pmids":["35098542"],"is_preprint":false},{"year":2015,"finding":"In human ovarian carcinoma ascites, PAPP-A (present at 46-fold higher concentration than in serum) is predominantly enzymatically active and drives IGFBP-4 cleavage; ascites has greater IGF-IR-activating potency than serum, and addition of recombinant PAPP-A to ascites further increased IGFBP-4 cleavage and IGF-IR activation, establishing PAPP-A proteolytic activity as the mechanism enhancing IGF bioactivity in ovarian cancer.","method":"IGFBP-4 cleavage assay in ascites; IGF-IR activation bioassay; immunohistochemistry on tumor tissue; addition of recombinant PAPP-A ex vivo","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ex vivo functional assay on human clinical samples with recombinant PAPP-A addition, single lab","pmids":["26336825"],"is_preprint":false},{"year":2016,"finding":"Human adipose tissue cultures secrete enzymatically active PAPP-A in a depot-specific manner: visceral adipose tissue (VAT) secretes ~4-fold more PAPP-A and generates more PAPP-A-cleaved IGFBP-4 fragments than subcutaneous adipose tissue (SAT), with correspondingly greater IGF-IR-activating potency in VAT conditioned medium.","method":"Human adipose tissue explant cultures (VAT and SAT); PAPP-A ELISA; intact and cleaved IGFBP-4 fragment immunoassays; IGF-IR activation bioassay","journal":"European journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct measurement of enzymatic activity and downstream IGF-IR activation from depot-specific primary human tissue cultures, single lab","pmids":["27585595"],"is_preprint":false},{"year":2016,"finding":"In human mesangial cells, IL-1β is the most potent stimulator of PAPP-A expression (~5-fold) followed by TNF-α (~2.5-fold); PAPP-A produced is secreted, cell-associated, and proteolytically active; IGF-1 complexed to wild-type but not protease-resistant IGFBP-4 stimulates mesangial cell proliferation, establishing that PAPP-A-mediated IGFBP-4 cleavage is required to release IGF-1 for mitogenic signaling in these cells.","method":"Primary human mesangial cell cultures; cytokine treatment; PAPP-A ELISA and activity assay; [3H]-thymidine incorporation proliferation assay with wild-type vs. protease-resistant IGFBP-4","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity measurement, protease-resistant IGFBP-4 as mechanistic control, functional proliferation assay; single lab","pmids":["27519211"],"is_preprint":false},{"year":2012,"finding":"CRP and TNF-α induce PAPP-A mRNA and protein expression in human peripheral blood mononuclear cells (PBMCs) in a dose- and time-dependent manner; this induction is mediated through the NF-κB pathway, as demonstrated by actinomycin D and NF-κB inhibitor (BAY11-7082) experiments.","method":"Human PBMC cultures; CRP and TNF-α stimulation; RT-PCR, Western blot, ELISA; actinomycin D (transcription inhibitor); NF-κB inhibitor BAY11-7082","journal":"Mediators of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — transcriptional and translational evidence with pathway inhibitor validation, single lab","pmids":["22997483"],"is_preprint":false},{"year":2014,"finding":"PAPP-A expression in human primary omental preadipocytes is preferentially elevated compared to mesenteric and subcutaneous preadipocytes; TNF-α and IL-1β upregulate PAPP-A expression via the NF-κB and JNK/p38 MAPK pathways; resveratrol downregulates PAPP-A expression under basal and stimulated conditions through SIRT1/AMPK-independent pathways.","method":"Primary human preadipocyte cultures from omental, mesenteric, and subcutaneous depots; cytokine treatment; pathway inhibitors; resveratrol treatment; qRT-PCR and protein assays","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — depot-specific primary human cells with pharmacological pathway dissection, single lab","pmids":["24781252"],"is_preprint":false},{"year":2010,"finding":"Heparin induces release of PAPP-A from normal arterial wall tissue (but not from non-arterial tissue or from atherosclerotic vulnerable plaques), suggesting that elevated circulating PAPP-A in acute coronary syndrome patients is due to heparin-mediated detachment from the arterial wall rather than secretion from vulnerable plaques.","method":"Immunohistochemistry on vulnerable plaques and control tissues; ex vivo heparin incubation of arterial vs. non-arterial tissue; PAPP-A measurement in volunteers receiving heparin","journal":"Clinical biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — negative finding for plaque localization combined with positive ex vivo tissue elution experiment, mechanistically informative","pmids":["21185276"],"is_preprint":false},{"year":2020,"finding":"Genetic or pharmacological (mAb-PA 1/41) inhibition of PAPP-A selectively reduces adipocyte size in visceral adipose tissue (VAT: mesenteric and pericardial) but not in subcutaneous adipose tissue (SAT) in mice on high-fat diet; in mesenteric fat, PAPP-A inhibition increased cell number (hyperplasia) alongside reduced hypertrophy, decreased macrophage marker (F4/80) and IL-6 expression, and increased adiponectin.","method":"Conditional PAPP-A gene knockdown in adult mice; anti-PAPP-A immunoneutralizing mAb (mAb-PA 1/41) in vivo; histology and adipocyte sizing; gene expression analysis","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two independent approaches (genetic KD and pharmacological antibody) yielding concordant depot-selective phenotype with molecular mechanistic readouts","pmids":["32888014"],"is_preprint":false},{"year":2024,"finding":"Sirtuin deficiency (any of SIRT1–SIRT7) drives chromatin rewiring via altered topologically associated domain (TAD) interactions and de novo enhancer-promoter loop formation, converging on aberrant transcriptional activation of the PAPPA gene; PAPPA mediates the pro-senescence effects downstream of sirtuin deficiency in human stem cells.","method":"Isogeneic human stem cell lines with SIRT1–SIRT7 knockouts; large-scale epigenomic analyses (Hi-C, ChIP-seq); 3D chromatin contact mapping; PAPPA knockdown in sirtuin-deficient cells; cellular senescence assays","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epigenomic and genetic approaches with functional senescence readout, single lab, novel regulatory mechanism","pmids":["38484732"],"is_preprint":false},{"year":1993,"finding":"The PAPPA gene was mapped to chromosomal region 9q33.1 by fluorescence in situ hybridization (FISH) using a 3.7-kb partial PAPPA cDNA probe on both mitotic and meiotic chromosomes.","method":"Fluorescence in situ hybridization (FISH) on mitotic and meiotic chromosomes","journal":"Cytogenetics and cell genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct chromosomal mapping by FISH, foundational genomic localization widely cited","pmids":["7679961"],"is_preprint":false}],"current_model":"PAPP-A (pappalysin-1) is a cell surface-associated zinc metzincin metalloproteinase that cleaves inhibitory IGF binding proteins (principally IGFBP-4, but also IGFBP-2 and IGFBP-5) in an IGF-dependent manner, thereby releasing bioactive IGF in the pericellular environment for IGF receptor activation; its proteolytic activity is endogenously inhibited by stanniocalcin-2 (STC2) via a covalent 2:2 complex in which STC2 sterically occludes IGFBP-4 substrate binding (established by cryo-EM structure), and PAPP-A also possesses at least one IGF-independent, non-proteolytic biological function revealed in zebrafish; transcriptional regulation of PAPPA occurs through inflammatory cytokines (via NF-κB), PPARγ, cAMP/CREB, and sirtuin-dependent chromatin rewiring, placing PAPP-A as a locally acting amplifier of IGF signaling with roles in fetal growth, ovarian steroidogenesis, adipose tissue remodeling, kidney homeostasis, bone marrow MSC maintenance, and cancer progression."},"narrative":{"mechanistic_narrative":"PAPP-A (pappalysin-1) is a cell surface-associated metzincin metalloproteinase that locally amplifies insulin-like growth factor (IGF) signaling by cleaving inhibitory IGF binding proteins in an IGF-dependent manner, principally IGFBP-4 but also IGFBP-2 and IGFBP-5, thereby liberating bioactive IGF for IGF receptor activation in the pericellular space [PMID:17218136, PMID:25617049]. Tight binding to cell-surface glycosaminoglycans positions PAPP-A to act locally on its substrates [PMID:17218136, PMID:25617049]. Structural work resolved how substrate engagement and inhibition occur: PAPP-A is a flexible trans-dimer whose central domain mediates both IGFBP recognition and trans-dimerization, with IGFBP5 captured via a 25-residue anchor peptide reaching into the active site; trans-dimer formation is required for efficient IGFBP-4 but not IGFBP-5 proteolysis [PMID:36127359]. Its proteolytic activity is endogenously suppressed by stanniocalcin-2 through a covalent 2:2 complex in which STC2 forms an intermolecular disulfide and sterically excludes IGFBP-4 from the substrate-binding region while leaving the catalytic site accessible to peptides [PMID:36257932]. Through this IGF-releasing activity PAPP-A acts as a local effector across tissues: it is required for ovarian steroidogenesis and female fertility [PMID:20130263], maternal adipose remodeling in pregnancy [PMID:33239385], and drives pathology in diabetic nephropathy, polycystic kidney disease, and multiple cancers via IGF-1R/PI3K/Akt signaling [PMID:31990681, PMID:22503545, PMID:26336825]. Inhibitory monoclonal antibodies targeting the IGFBP-4-cleavage exosite suppress AKT signaling and tumor growth, establishing the proteolytic function as therapeutically tractable [PMID:24572990, PMID:31990681]. PAPP-A transcription is induced by inflammatory cytokines via NF-κB, repressed by PPARγ, and activated by cAMP/CREB and by sirtuin-deficiency-driven chromatin rewiring linked to senescence [PMID:22997483, PMID:16388849, PMID:31990681, PMID:38484732]. Beyond its protease function, PAPP-A also possesses at least one IGF-independent biological activity, demonstrated in zebrafish where a catalytically dead protein rescues a developmental phenotype [PMID:23430244].","teleology":[{"year":1979,"claim":"Before any enzymatic role was known, the first question was simply what kind of protein PAPP-A is; early purification defined it as a large, acidic glycoprotein and tentatively assigned in vitro effects on coagulation and complement.","evidence":"Protein purification and in vitro complement/plasmin/coagulation inhibition assays","pmids":["518134"],"confidence":"Medium","gaps":["The coagulation/complement activities were not corroborated by later mechanistic work","No catalytic or substrate identity established at this stage"]},{"year":1983,"claim":"Refining the early biochemical picture, the anticoagulant effect was shown to act indirectly via antithrombin III activation and to depend on strongly acidic (heparin-like) residues, hinting at the charged surface properties later relevant to glycosaminoglycan binding.","evidence":"In vitro coagulation assay with antithrombin III titration and protamine sulfate neutralization","pmids":["6197764"],"confidence":"Medium","gaps":["Physiological relevance of anticoagulant activity unestablished","No connection to a catalytic mechanism"]},{"year":1993,"claim":"Genomic localization was needed to enable molecular study; FISH mapped PAPPA to 9q33.1.","evidence":"Fluorescence in situ hybridization on mitotic and meiotic chromosomes","pmids":["7679961"],"confidence":"High","gaps":["Mapping alone provides no functional information"]},{"year":1999,"claim":"The defining mechanistic breakthrough resolved what PAPP-A actually does: it is the long-sought IGF-dependent IGFBP-4 protease, cleaving IGFBP-4 only when IGF is bound and thereby releasing bioactive IGF.","evidence":"Biochemical purification and protease activity assay from human fibroblast conditioned media","pmids":["17218136"],"confidence":"High","gaps":["Did not define catalytic mechanism or structural basis of IGF dependence","Full substrate repertoire not yet established"]},{"year":2007,"claim":"Synthesizing across studies established PAPP-A as a metzincin metalloproteinase that cleaves IGFBP-4/-2/-5 and binds cell-surface glycosaminoglycans, positioning it as a local amplifier of pericellular IGF signaling.","evidence":"Review integrating biochemical assays, cell-surface binding experiments, and knockout mouse data","pmids":["17218136","25617049"],"confidence":"High","gaps":["Structural basis of cell-surface tethering not resolved","How catalysis is regulated in vivo unclear"]},{"year":2010,"claim":"To test physiological necessity of the protease activity, knockout mice showed loss of ovarian IGFBP-4 proteolysis causes reduced ovulation, lowered steroid hormones, and impaired fertility, establishing an in vivo reproductive role.","evidence":"Pappa knockout mouse with follicular IGFBP-4 activity assay, serum hormone, and ovarian gene expression","pmids":["20130263"],"confidence":"High","gaps":["Did not separate proteolytic from non-proteolytic contributions","Upstream regulation of ovarian PAPP-A not addressed"]},{"year":2013,"claim":"A pivotal question was whether PAPP-A function is solely proteolytic; rescue of a zebrafish developmental phenotype by catalytically dead protein demonstrated a biologically important IGF-independent, non-proteolytic function.","evidence":"Zebrafish morpholino knockdown rescued by wild-type vs. active-site-mutant papp-a mRNA","pmids":["23430244"],"confidence":"High","gaps":["Molecular identity of the non-proteolytic function unknown","No partner or pathway for this activity identified"]},{"year":2014,"claim":"To establish therapeutic tractability and confirm that IGFBP-4 cleavage drives pericellular IGF signaling, an exosite-targeting inhibitory antibody suppressed AKT signaling and tumor growth.","evidence":"Inhibitory mAb (Ki=135 pM), AKT phosphorylation assay, and A549 xenograft model","pmids":["24572990"],"confidence":"High","gaps":["Tested in a single tumor model","Did not address resistance or systemic effects"]},{"year":2022,"claim":"The structural basis of endogenous inhibition and substrate recognition was resolved: STC2 inhibits PAPP-A by covalent disulfide locking and steric substrate exclusion, while a separate structure showed PAPP-A as a trans-dimer engaging IGFBP via an anchor peptide reaching the active site.","evidence":"Single-particle cryo-EM of the 2:2 PAPP-A·STC2 complex and of inactive PAPP-A(E483A) with an IGFBP5 peptide, plus mutagenesis and cleavage assays","pmids":["36257932","36127359"],"confidence":"High","gaps":["Structures cover N-terminal/central regions; full-length conformational dynamics incomplete","Structural basis of cell-surface and glycosaminoglycan binding not resolved"]},{"year":2020,"claim":"Recurring questions about tissue-specific roles were addressed by knockout and antibody studies showing PAPP-A drives cyst growth in polycystic kidney disease, maternal adipose remodeling, and depot-selective visceral adiposity through IGF bioavailability.","evidence":"Pappa KO and anti-PAPP-A mAb in Pkd1 and high-fat-diet mouse models, ex vivo human adipose assays with pathway-specific neutralization","pmids":["31990681","33239385","32888014"],"confidence":"High","gaps":["Mechanism of depot selectivity not fully resolved","Whether non-proteolytic function contributes to these phenotypes untested"]},{"year":2019,"claim":"In cancer, CRISPR and antibody studies established PAPP-A as essential for tumor cell survival and metastasis, acting via local IGF-1 bioavailability and, in mammary metastasis, the collagen receptor DDR2.","evidence":"CRISPR knockout, RNA-seq, and xenograft in Ewing sarcoma; DDR2 CRISPR epistasis and collagen imaging in mammary models","pmids":["30698726","31046834"],"confidence":"High","gaps":["Link between PAPP-A protease activity and DDR2 activation not mechanistically resolved","Interferon/immune-evasion connection in EWS correlative"]},{"year":2024,"claim":"Transcriptional control of PAPPA was progressively mapped to inflammatory cytokine/NF-κB and JNK/p38 signaling, PPARγ repression, cAMP/CREB activation, and sirtuin-deficiency-driven chromatin rewiring that converges on PAPPA to mediate senescence.","evidence":"Cytokine and pathway-inhibitor studies in PBMCs, mesangial cells, and preadipocytes; PPARγ agonist in trophoblasts; Hi-C/ChIP-seq with PAPPA knockdown in sirtuin-KO stem cells","pmids":["22997483","27519211","24781252","16388849","38484732"],"confidence":"Medium","gaps":["Direct PAPPA promoter/enhancer elements not fully defined","Integration of these regulatory inputs in vivo unclear"]},{"year":null,"claim":"The molecular identity and partners of the IGF-independent, non-proteolytic PAPP-A function remain undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No effector or pathway identified for the non-proteolytic activity","Whether it operates in mammalian tissues is untested","No structural correlate of a non-catalytic function"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,5,6,7]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,3,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,9]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[13,21,22,23]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,12,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,15,19,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,8,10,13]}],"complexes":["PAPP-A·STC2 2:2 inhibitory complex","PAPP-A trans-dimer"],"partners":["IGFBP4","IGFBP5","IGFBP2","STC2","IGF1","DDR2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13219","full_name":"Pappalysin-1","aliases":["Insulin-like growth factor-dependent IGF-binding protein 4 protease","IGF-dependent IGFBP-4 protease","IGFBP-4ase","Pregnancy-associated plasma protein A","PAPP-A"],"length_aa":1627,"mass_kda":181.0,"function":"Metalloproteinase which specifically cleaves IGFBP-4 and IGFBP-5, resulting in release of bound IGF. Cleavage of IGFBP-4 is dramatically enhanced by the presence of IGF, whereas cleavage of IGFBP-5 is slightly inhibited by the presence of IGF","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q13219/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PAPPA","classification":"Not Classified","n_dependent_lines":29,"n_total_lines":1208,"dependency_fraction":0.024006622516556293},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PAPPA","total_profiled":1310},"omim":[{"mim_id":"620900","title":"SHORT TANDEM REPEAT, TTTG(4), THYROID-SPECIFIC; STRTS","url":"https://www.omim.org/entry/620900"},{"mim_id":"620899","title":"MICRO RNA 1179; MIR1179","url":"https://www.omim.org/entry/620899"},{"mim_id":"620898","title":"MICRO RNA 7-2; MIR7-2","url":"https://www.omim.org/entry/620898"},{"mim_id":"619663","title":"UTP25 SMALL SUBUNIT PROCESSOR COMPONENT; UTP25","url":"https://www.omim.org/entry/619663"},{"mim_id":"619485","title":"PAPPALYSIN 2; PAPPA2","url":"https://www.omim.org/entry/619485"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":68.1}],"url":"https://www.proteinatlas.org/search/PAPPA"},"hgnc":{"alias_symbol":["PAPP-A","PAPPA1","IGFBP-4ase","PAPA","ASBABP2","DIPLA1"],"prev_symbol":[]},"alphafold":{"accession":"Q13219","domains":[{"cath_id":"2.60.120.200","chopping":"96-311","consensus_level":"high","plddt":85.0405,"start":96,"end":311},{"cath_id":"3.40.390.10","chopping":"349-409_497-571","consensus_level":"medium","plddt":90.3845,"start":349,"end":571},{"cath_id":"-","chopping":"414-494","consensus_level":"medium","plddt":81.8486,"start":414,"end":494},{"cath_id":"-","chopping":"573-647","consensus_level":"medium","plddt":83.0528,"start":573,"end":647},{"cath_id":"2.60.40.10","chopping":"681-700_883-980","consensus_level":"medium","plddt":85.7669,"start":681,"end":980},{"cath_id":"2.60.120.260","chopping":"711-881","consensus_level":"high","plddt":83.1964,"start":711,"end":881},{"cath_id":"2.60.120.260","chopping":"1009-1197","consensus_level":"high","plddt":79.693,"start":1009,"end":1197},{"cath_id":"-","chopping":"1224-1283","consensus_level":"high","plddt":68.1272,"start":1224,"end":1283},{"cath_id":"2.10.70.10","chopping":"1356-1413","consensus_level":"medium","plddt":80.1002,"start":1356,"end":1413}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13219","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13219-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13219-F1-predicted_aligned_error_v6.png","plddt_mean":79.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PAPPA","jax_strain_url":"https://www.jax.org/strain/search?query=PAPPA"},"sequence":{"accession":"Q13219","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13219.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13219/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13219"}},"corpus_meta":[{"pmid":"17218136","id":"PMC_17218136","title":"Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs.","date":"2007","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/17218136","citation_count":153,"is_preprint":false},{"pmid":"25617049","id":"PMC_25617049","title":"The role of PAPP-A in the IGF system: location, location, location.","date":"2015","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/25617049","citation_count":153,"is_preprint":false},{"pmid":"12224070","id":"PMC_12224070","title":"Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.","date":"2002","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/12224070","citation_count":142,"is_preprint":false},{"pmid":"18000943","id":"PMC_18000943","title":"Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.","date":"2008","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/18000943","citation_count":140,"is_preprint":false},{"pmid":"28012202","id":"PMC_28012202","title":"Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis.","date":"2017","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/28012202","citation_count":87,"is_preprint":false},{"pmid":"518134","id":"PMC_518134","title":"Purification and characterization of pregnancy associated plasma protein A (PAPP-A).","date":"1979","source":"Archives of gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/518134","citation_count":78,"is_preprint":false},{"pmid":"10820406","id":"PMC_10820406","title":"Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester.","date":"2000","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/10820406","citation_count":69,"is_preprint":false},{"pmid":"22503545","id":"PMC_22503545","title":"PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling pathway.","date":"2012","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/22503545","citation_count":69,"is_preprint":false},{"pmid":"7533285","id":"PMC_7533285","title":"Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome.","date":"1994","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/7533285","citation_count":67,"is_preprint":false},{"pmid":"20130263","id":"PMC_20130263","title":"Lack of functional pregnancy-associated plasma protein-A (PAPPA) compromises mouse ovarian steroidogenesis and female fertility.","date":"2010","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/20130263","citation_count":62,"is_preprint":false},{"pmid":"29758559","id":"PMC_29758559","title":"CircRNA-0004904, CircRNA-0001855, and PAPP-A: Potential Novel Biomarkers for the Prediction of Preeclampsia.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29758559","citation_count":61,"is_preprint":false},{"pmid":"16635455","id":"PMC_16635455","title":"PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis.","date":"2006","source":"American journal of obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/16635455","citation_count":58,"is_preprint":false},{"pmid":"18789800","id":"PMC_18789800","title":"Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18789800","citation_count":56,"is_preprint":false},{"pmid":"29864720","id":"PMC_29864720","title":"IGFBP-4 and PAPP-A in normal physiology and disease.","date":"2018","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/29864720","citation_count":54,"is_preprint":false},{"pmid":"30698726","id":"PMC_30698726","title":"Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.","date":"2019","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/30698726","citation_count":54,"is_preprint":false},{"pmid":"24572990","id":"PMC_24572990","title":"Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24572990","citation_count":51,"is_preprint":false},{"pmid":"27155776","id":"PMC_27155776","title":"PAPP-A and the IGF system.","date":"2016","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/27155776","citation_count":49,"is_preprint":false},{"pmid":"19003798","id":"PMC_19003798","title":"First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses.","date":"2008","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/19003798","citation_count":49,"is_preprint":false},{"pmid":"37267421","id":"PMC_37267421","title":"The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story.","date":"2023","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37267421","citation_count":48,"is_preprint":false},{"pmid":"27618784","id":"PMC_27618784","title":"mTOR regulates the expression of DNA damage response enzymes in long-lived Snell dwarf, GHRKO, and PAPPA-KO mice.","date":"2016","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/27618784","citation_count":48,"is_preprint":false},{"pmid":"24381414","id":"PMC_24381414","title":"First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.","date":"2012","source":"Indian journal of clinical biochemistry : IJCB","url":"https://pubmed.ncbi.nlm.nih.gov/24381414","citation_count":44,"is_preprint":false},{"pmid":"29844094","id":"PMC_29844094","title":"PAPP-A and cancer.","date":"2018","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29844094","citation_count":43,"is_preprint":false},{"pmid":"33239385","id":"PMC_33239385","title":"PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33239385","citation_count":42,"is_preprint":false},{"pmid":"36718521","id":"PMC_36718521","title":"The Stanniocalcin-PAPP-A-IGFBP-IGF Axis.","date":"2023","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36718521","citation_count":40,"is_preprint":false},{"pmid":"31138428","id":"PMC_31138428","title":"The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome.","date":"2019","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/31138428","citation_count":40,"is_preprint":false},{"pmid":"16388849","id":"PMC_16388849","title":"Modulation of PAPP-A expression by PPARgamma in human first trimester trophoblast.","date":"2006","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/16388849","citation_count":40,"is_preprint":false},{"pmid":"24783354","id":"PMC_24783354","title":"Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia.","date":"2014","source":"Advances in clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24783354","citation_count":39,"is_preprint":false},{"pmid":"12744930","id":"PMC_12744930","title":"Expression of pregnancy-associated plasma protein-A (PAPP-A) during human villous trophoblast differentiation in vitro.","date":"2003","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/12744930","citation_count":39,"is_preprint":false},{"pmid":"6169364","id":"PMC_6169364","title":"Pregnancy-associated plasma protein-A (PAPP-A) and hCG in early pregnancy.","date":"1981","source":"British journal of obstetrics and gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/6169364","citation_count":34,"is_preprint":false},{"pmid":"38484732","id":"PMC_38484732","title":"The sirtuin-associated human senescence program converges on the activation of placenta-specific gene PAPPA.","date":"2024","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/38484732","citation_count":32,"is_preprint":false},{"pmid":"26106266","id":"PMC_26106266","title":"Combination of PAPPA, fhCGβ, AFP, PlGF, sTNFR1, and Maternal Characteristics in Prediction of Early-onset Preeclampsia.","date":"2015","source":"Clinical medicine insights. Reproductive health","url":"https://pubmed.ncbi.nlm.nih.gov/26106266","citation_count":31,"is_preprint":false},{"pmid":"26336825","id":"PMC_26336825","title":"PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26336825","citation_count":30,"is_preprint":false},{"pmid":"24757339","id":"PMC_24757339","title":"Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.","date":"2013","source":"Journal of obstetrics and gynaecology of India","url":"https://pubmed.ncbi.nlm.nih.gov/24757339","citation_count":30,"is_preprint":false},{"pmid":"28035757","id":"PMC_28035757","title":"PAPP-A: a promising therapeutic target for healthy longevity.","date":"2016","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28035757","citation_count":29,"is_preprint":false},{"pmid":"27585595","id":"PMC_27585595","title":"PAPP-A, IGFBP-4 and IGF-II are secreted by human adipose tissue cultures in a depot-specific manner.","date":"2016","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27585595","citation_count":29,"is_preprint":false},{"pmid":"33388371","id":"PMC_33388371","title":"Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33388371","citation_count":28,"is_preprint":false},{"pmid":"36257932","id":"PMC_36257932","title":"Structure of the proteolytic enzyme PAPP-A with the endogenous inhibitor stanniocalcin-2 reveals its inhibitory mechanism.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36257932","citation_count":28,"is_preprint":false},{"pmid":"28419502","id":"PMC_28419502","title":"Nuchal translucency measurement, free β-hCG and PAPP-A concentrations in IVF/ICSI pregnancies: systematic review and meta-analysis.","date":"2017","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/28419502","citation_count":28,"is_preprint":false},{"pmid":"21185276","id":"PMC_21185276","title":"Pregnancy associated plasma protein-A (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque.","date":"2010","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21185276","citation_count":28,"is_preprint":false},{"pmid":"25489725","id":"PMC_25489725","title":"PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI.","date":"2014","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25489725","citation_count":28,"is_preprint":false},{"pmid":"16712749","id":"PMC_16712749","title":"[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?].","date":"2006","source":"Revista espanola de cardiologia","url":"https://pubmed.ncbi.nlm.nih.gov/16712749","citation_count":28,"is_preprint":false},{"pmid":"26726121","id":"PMC_26726121","title":"Maternal serum PAPP-A and free β-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.","date":"2016","source":"Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/26726121","citation_count":27,"is_preprint":false},{"pmid":"23430244","id":"PMC_23430244","title":"Pregnancy-associated plasma protein A (PAPP-A) modulates the early developmental rate in zebrafish independently of its proteolytic activity.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23430244","citation_count":26,"is_preprint":false},{"pmid":"31990681","id":"PMC_31990681","title":"Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31990681","citation_count":25,"is_preprint":false},{"pmid":"7679961","id":"PMC_7679961","title":"Assignment of the human gene for pregnancy-associated plasma protein A (PAPPA) to 9q33.1 by fluorescence in situ hybridization to mitotic and meiotic chromosomes.","date":"1993","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7679961","citation_count":25,"is_preprint":false},{"pmid":"20854420","id":"PMC_20854420","title":"PAPP-A: a new anti-aging target?","date":"2010","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/20854420","citation_count":24,"is_preprint":false},{"pmid":"29532882","id":"PMC_29532882","title":"Placental expression of PAPPA, PAPPA-2 and PLAC-1 in pregnacies is associated with FGR.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29532882","citation_count":24,"is_preprint":false},{"pmid":"24781252","id":"PMC_24781252","title":"Preferential expression of PAPPA in human preadipocytes from omental fat.","date":"2014","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24781252","citation_count":24,"is_preprint":false},{"pmid":"32198414","id":"PMC_32198414","title":"First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32198414","citation_count":23,"is_preprint":false},{"pmid":"32684596","id":"PMC_32684596","title":"MiR-182-5p Inhibits the Proliferation of Vascular Smooth Muscle Cells Induced by ox-LDL Through Targeting PAPPA.","date":"2020","source":"International heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/32684596","citation_count":23,"is_preprint":false},{"pmid":"12213189","id":"PMC_12213189","title":"Differential regulation of pregnancy associated plasma protein (PAPP)-A during pregnancy in human and mouse.","date":"2002","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/12213189","citation_count":23,"is_preprint":false},{"pmid":"23881937","id":"PMC_23881937","title":"Mice deficient in PAPP-A show resistance to the development of diabetic nephropathy.","date":"2013","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23881937","citation_count":23,"is_preprint":false},{"pmid":"20013873","id":"PMC_20013873","title":"Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia.","date":"2010","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/20013873","citation_count":22,"is_preprint":false},{"pmid":"22148978","id":"PMC_22148978","title":"βhCG and PAPP-A in first trimester: predictive factors for preeclampsia?","date":"2011","source":"Hypertension in pregnancy","url":"https://pubmed.ncbi.nlm.nih.gov/22148978","citation_count":22,"is_preprint":false},{"pmid":"31046834","id":"PMC_31046834","title":"Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.","date":"2019","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/31046834","citation_count":22,"is_preprint":false},{"pmid":"31518159","id":"PMC_31518159","title":"PAPP-A and the IGF system in atherosclerosis: what's up, what's down?","date":"2019","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31518159","citation_count":21,"is_preprint":false},{"pmid":"22778981","id":"PMC_22778981","title":"PP13 and PAPP-A in the First and Second Trimesters: Predictive Factors for Preeclampsia?","date":"2012","source":"ISRN obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/22778981","citation_count":21,"is_preprint":false},{"pmid":"26417939","id":"PMC_26417939","title":"ADAM12 and PAPP-A: Candidate regulators of trophoblast invasion and first trimester markers of healthy trophoblasts.","date":"2015","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/26417939","citation_count":20,"is_preprint":false},{"pmid":"17376420","id":"PMC_17376420","title":"Measurement and clinical significance of circulating PAPP-A in ACS patients.","date":"2007","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17376420","citation_count":20,"is_preprint":false},{"pmid":"12448565","id":"PMC_12448565","title":"Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.","date":"2002","source":"Bratislavske lekarske listy","url":"https://pubmed.ncbi.nlm.nih.gov/12448565","citation_count":20,"is_preprint":false},{"pmid":"17714879","id":"PMC_17714879","title":"PAPP-A: a possible pathogenic link to the instability of atherosclerotic plaque.","date":"2007","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/17714879","citation_count":20,"is_preprint":false},{"pmid":"30025286","id":"PMC_30025286","title":"Characterization of mouse pericardial fat: regulation by PAPP-A.","date":"2018","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/30025286","citation_count":20,"is_preprint":false},{"pmid":"24333852","id":"PMC_24333852","title":"Development of a recombinant antibody towards PAPP-A for immunohistochemical use in multiple animal species.","date":"2013","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/24333852","citation_count":20,"is_preprint":false},{"pmid":"23262366","id":"PMC_23262366","title":"PAPP-A in cardiac and non-cardiac conditions.","date":"2012","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23262366","citation_count":19,"is_preprint":false},{"pmid":"22790018","id":"PMC_22790018","title":"Role of PAPP-A in aging and age-related disease.","date":"2012","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/22790018","citation_count":19,"is_preprint":false},{"pmid":"31335241","id":"PMC_31335241","title":"PAPP-A concentrations change in patients with gestational diabetes.","date":"2019","source":"Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/31335241","citation_count":18,"is_preprint":false},{"pmid":"34974815","id":"PMC_34974815","title":"Pregnancy-associated plasma protein-A (PAPPA) promotes breast cancer progression.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34974815","citation_count":17,"is_preprint":false},{"pmid":"26031184","id":"PMC_26031184","title":"Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle.","date":"2015","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/26031184","citation_count":17,"is_preprint":false},{"pmid":"33515274","id":"PMC_33515274","title":"First trimester serum PAPP-A is associated with placenta accreta: a retrospective study.","date":"2021","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/33515274","citation_count":16,"is_preprint":false},{"pmid":"26544105","id":"PMC_26544105","title":"First trimester PAPP-A2, PAPP-A and hCGβ in small-for-gestational-age pregnancies.","date":"2016","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26544105","citation_count":16,"is_preprint":false},{"pmid":"26654447","id":"PMC_26654447","title":"Placental DNA methylation at term reflects maternal serum levels of INHA and FN1, but not PAPPA, early in pregnancy.","date":"2015","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26654447","citation_count":16,"is_preprint":false},{"pmid":"12749035","id":"PMC_12749035","title":"Frequency and clinical consequences of extremely high maternal serum PAPP-A levels.","date":"2003","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/12749035","citation_count":16,"is_preprint":false},{"pmid":"35098542","id":"PMC_35098542","title":"Pregnancy-associated plasma protein-A (PAPP-A) is a key component of an interactive cellular mechanism promoting pulmonary fibrosis.","date":"2022","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35098542","citation_count":15,"is_preprint":false},{"pmid":"28627818","id":"PMC_28627818","title":"Maternal Serum PLGF, PAPPA, β-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia.","date":"2017","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/28627818","citation_count":15,"is_preprint":false},{"pmid":"33235026","id":"PMC_33235026","title":"Knockdown of H19 Attenuates Ox-LDL-induced Vascular Smooth Muscle Cell Proliferation, Migration, and Invasion by Regulating miR-599/PAPPA Axis.","date":"2021","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33235026","citation_count":14,"is_preprint":false},{"pmid":"31519945","id":"PMC_31519945","title":"A common variant of the pregnancy-associated plasma protein-A (PAPPA) gene encodes a protein with reduced proteolytic activity towards IGF-binding proteins.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31519945","citation_count":14,"is_preprint":false},{"pmid":"28964325","id":"PMC_28964325","title":"Physiological parameters regulating circulating levels of the IGFBP-4/Stanniocalcin-2/PAPP-A axis.","date":"2017","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/28964325","citation_count":14,"is_preprint":false},{"pmid":"27519211","id":"PMC_27519211","title":"PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.","date":"2016","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27519211","citation_count":14,"is_preprint":false},{"pmid":"29211611","id":"PMC_29211611","title":"Pregnancy-associated plasma protein-A (PAPP-A) levels in patients with severe allergic asthma are reduced by omalizumab.","date":"2017","source":"The Journal of asthma : official journal of the Association for the Care of Asthma","url":"https://pubmed.ncbi.nlm.nih.gov/29211611","citation_count":13,"is_preprint":false},{"pmid":"33508770","id":"PMC_33508770","title":"Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33508770","citation_count":13,"is_preprint":false},{"pmid":"22021032","id":"PMC_22021032","title":"PAPP-A and free β-hCG in relation to admission to neonatal intensive care unit and neonatal disease.","date":"2011","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/22021032","citation_count":13,"is_preprint":false},{"pmid":"6197764","id":"PMC_6197764","title":"Pregnancy-associated plasma protein-A (PAPP-A) inhibits thrombin-induced coagulation of plasma.","date":"1983","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/6197764","citation_count":13,"is_preprint":false},{"pmid":"21268036","id":"PMC_21268036","title":"PAPP-A and free β-hCG measured prior to 10 weeks is associated with preterm delivery and small-for-gestational-age infants.","date":"2011","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/21268036","citation_count":13,"is_preprint":false},{"pmid":"32470448","id":"PMC_32470448","title":"Long non-coding RNA MIAT/miR-148b/PAPPA axis modifies cell proliferation and migration in ox-LDL-induced human aorta vascular smooth muscle cells.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32470448","citation_count":12,"is_preprint":false},{"pmid":"36127359","id":"PMC_36127359","title":"Structure of the PAPP-ABP5 complex reveals mechanism of substrate recognition.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36127359","citation_count":12,"is_preprint":false},{"pmid":"37778995","id":"PMC_37778995","title":"Exosomes Promote Atherosclerosis Progression by Regulating Circ_100696/miR-503-5p/PAPPA Axis-Mediated Vascular Smooth Muscle Cells Proliferation and Migration.","date":"2023","source":"International heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/37778995","citation_count":12,"is_preprint":false},{"pmid":"33561324","id":"PMC_33561324","title":"Inhibition of longevity regulator PAPP-A modulates tissue homeostasis via restraint of mesenchymal stromal cells.","date":"2021","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/33561324","citation_count":12,"is_preprint":false},{"pmid":"17976018","id":"PMC_17976018","title":"Activity of ulilysin, an archaeal PAPP-A-related gelatinase and IGFBP protease.","date":"2007","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17976018","citation_count":12,"is_preprint":false},{"pmid":"31631239","id":"PMC_31631239","title":"Collagen and PAPP-A in the Etiology of Postpartum Breast Cancer.","date":"2019","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31631239","citation_count":11,"is_preprint":false},{"pmid":"39631521","id":"PMC_39631521","title":"First-Trimester PlGF and PAPP-A and the Risk of Placenta-Mediated Complications: PREDICTION Prospective Study.","date":"2024","source":"Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC","url":"https://pubmed.ncbi.nlm.nih.gov/39631521","citation_count":11,"is_preprint":false},{"pmid":"32901383","id":"PMC_32901383","title":"The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning.","date":"2020","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/32901383","citation_count":11,"is_preprint":false},{"pmid":"34093757","id":"PMC_34093757","title":"Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34093757","citation_count":11,"is_preprint":false},{"pmid":"34285657","id":"PMC_34285657","title":"lncRNA PAPPA-AS1 Induces the Development of Hypertrophic Scar by Upregulating TLR4 through Interacting with TAF15.","date":"2021","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34285657","citation_count":11,"is_preprint":false},{"pmid":"21533533","id":"PMC_21533533","title":"PAPP-A levels of late pregnancy in preeclampsia and HELLP syndrome.","date":"2011","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/21533533","citation_count":11,"is_preprint":false},{"pmid":"6202314","id":"PMC_6202314","title":"Pregnancy-associated plasma protein A (PAPP-A) in non-pregnant subjects.","date":"1984","source":"British journal of obstetrics and gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/6202314","citation_count":11,"is_preprint":false},{"pmid":"32569826","id":"PMC_32569826","title":"Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32569826","citation_count":10,"is_preprint":false},{"pmid":"32888014","id":"PMC_32888014","title":"Genetic and Pharmacological Inhibition of PAPP-A Protects Against Visceral Obesity in Mice.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32888014","citation_count":10,"is_preprint":false},{"pmid":"36917422","id":"PMC_36917422","title":"Higher PAPP-A Values in Pregnant Women Complicated with Preeclampsia Than with Gestational Hypertension.","date":"2023","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/36917422","citation_count":10,"is_preprint":false},{"pmid":"22997483","id":"PMC_22997483","title":"CRP and TNF-α  induce PAPP-A expression in human peripheral blood mononuclear cells.","date":"2012","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22997483","citation_count":10,"is_preprint":false},{"pmid":"36131518","id":"PMC_36131518","title":"First trimester low maternal serum pregnancy associated plasma protein-A (PAPP-A) as a screening method for adverse pregnancy outcomes.","date":"2022","source":"Journal of perinatal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36131518","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50840,"output_tokens":8117,"usd":0.137137,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17772,"output_tokens":4338,"usd":0.098655,"stage2_stop_reason":"end_turn"},"total_usd":0.235792,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"PAPP-A was identified as the IGF-dependent IGFBP-4 protease activity present in conditioned media from human fibroblasts; it cleaves IGFBP-4 only when IGF is bound to IGFBP-4, releasing bioactive IGF.\",\n      \"method\": \"Biochemical purification and protease activity assay from human fibroblast conditioned media\",\n      \"journal\": \"Growth hormone & IGF research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — foundational biochemical purification and enzymatic characterization, independently replicated and widely accepted as the defining function of PAPP-A\",\n      \"pmids\": [\"17218136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1979,\n      \"finding\": \"PAPP-A was purified and characterized as an alpha-2 glycoprotein of ~750–820 kDa, likely a dimer composed of two polypeptide chains of ~218 kDa each; in vitro it inhibited complement activity, caseinolytic activity of plasmin, and thrombin-induced coagulation via activation of antithrombin III.\",\n      \"method\": \"Protein purification (ammonium sulfate precipitation, ion-exchange, affinity chromatography, gel filtration); in vitro complement, plasmin, and coagulation inhibition assays\",\n      \"journal\": \"Archives of gynecology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct biochemical characterization in a single early study; functional roles in coagulation/complement not widely corroborated in later work\",\n      \"pmids\": [\"518134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Purified PAPP-A inhibits thrombin-induced coagulation of plasma by activating endogenous antithrombin III (not by direct inhibition of thrombin); this inhibitory effect is neutralized by protamine sulfate, suggesting PAPP-A carries strongly acidic (heparin-like) residues.\",\n      \"method\": \"In vitro coagulation assay with purified PAPP-A, euglobulin system, antithrombin III titration, protamine sulfate neutralization\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro biochemical assay with mechanistic dissection, single laboratory\",\n      \"pmids\": [\"6197764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PAPP-A is a metzincin metalloproteinase that cleaves IGFBP-4 (and IGFBP-2 and IGFBP-5) in an IGF-dependent manner; it is cell surface-associated via tight binding to glycosaminoglycans, positioning it to increase local IGF bioavailability for IGF receptor activation.\",\n      \"method\": \"Review of biochemical assays, cell-surface binding experiments, and PAPP-A knockout mouse studies\",\n      \"journal\": \"Growth hormone & IGF research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods across multiple laboratories establish IGFBP protease activity, cell-surface binding, and in vivo IGF regulation\",\n      \"pmids\": [\"17218136\", \"25617049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PAPP-A knockout (KO) female mice show complete loss of ovarian IGFBP-4 proteolytic activity, reduced ovulated oocyte numbers, lower estradiol and progesterone levels, and reduced steroidogenic enzyme gene expression, demonstrating that PAPP-A-mediated IGFBP-4 cleavage is required for normal ovarian steroidogenesis and female fertility.\",\n      \"method\": \"Pappa gene-targeted knockout mouse; IGFBP-4 proteolytic activity assay in follicular fluid; serum hormone measurement; ovarian gene expression analysis\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with multiple orthogonal phenotypic readouts (activity assay, hormone levels, gene expression) in a single well-characterized genetic model\",\n      \"pmids\": [\"20130263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"An inhibitory monoclonal antibody (mAb 1/41) targeting a substrate-binding exosite of PAPP-A selectively inhibits IGFBP-4 cleavage (Ki = 135 pM), suppresses IGF receptor (AKT) signaling in lung cancer cells, and inhibits tumor growth in a murine A549 xenograft model, establishing that PAPP-A's proteolytic activity toward IGFBP-4 is required for pericellular IGF signaling.\",\n      \"method\": \"Inhibitory monoclonal antibody development; in vitro IGFBP-4 cleavage assay; AKT phosphorylation assay in cell monolayers; murine xenograft tumor model; tumor tissue immunohistochemistry\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — exosite-targeting antibody with defined Ki, in vitro signaling assay, and in vivo xenograft validation in single lab with multiple orthogonal readouts\",\n      \"pmids\": [\"24572990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of the 500 kDa 2:2 PAPP-A·stanniocalcin-2 (STC2) complex (3.1 Å for the STC2 and N-terminal ~1000 residues of PAPP-A) revealed that STC2 inhibits PAPP-A via: (1) a specific intermolecular disulfide bond preventing dissociation, and (2) interactions between STC2 and the very C-terminal module of PAPP-A that sterically prevent IGFBP-4 binding; the catalytic active site remains accessible to synthetic peptides, establishing an unusual substrate-exclusion mechanism of inhibition.\",\n      \"method\": \"Single-particle cryo-electron microscopy (cryo-EM); synthetic peptide hydrolysis assay; biochemical characterization of PAPP-A·STC2 complex\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structure with biochemical validation of inhibitory mechanism, published in peer-reviewed journal\",\n      \"pmids\": [\"36257932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structures of catalytically inactive PAPP-A(E483A) alone and in complex with an IGFBP5 peptide revealed that PAPP-A is a flexible trans-dimer that binds IGFBP5 via a unique 25-amino acid anchor peptide extending into the metalloprotease active site; the central domain of PAPP-A mediates both IGFBP5 recognition and trans-dimerization; trans-dimer formation and distal inter-domain interactions are required for efficient proteolysis of IGFBP4 but dispensable for IGFBP5 cleavage.\",\n      \"method\": \"Single-particle cryo-EM; AlphaFold-assisted model building; active-site mutant (E483A); biochemical proteolysis assays with IGFBP4 and IGFBP5\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure with mutagenesis and in vitro cleavage assays in a single rigorous study\",\n      \"pmids\": [\"36127359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In zebrafish, knockdown of papp-a slows developmental rate beginning at gastrulation; this phenotype is rescued by proteolytically inactive Papp-a mRNA as efficiently as wild-type, demonstrating that Papp-a has a biologically important function independent of its IGFBP proteolytic activity.\",\n      \"method\": \"Zebrafish morpholino knockdown; rescue with wild-type vs. proteolytically inactive (active-site mutant) Papp-a mRNA; in vitro recombinant proteolytic activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — genetic knockdown with rescue by catalytic mutant, supported by biochemical confirmation of activity loss, demonstrating non-proteolytic function\",\n      \"pmids\": [\"23430244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PAPP-A is expressed on the cell surface of Ewing sarcoma (EWS) cells; CRISPR/Cas9 knockout of PAPPA revealed an essential survival role through local IGF-1 bioavailability regulation; PAPPA knockout also induced interferon-response genes involved in antigen processing/presentation, linking PAPP-A to immune evasion in EWS.\",\n      \"method\": \"CRISPR/Cas9 knockout; anti-PAPP-A antibody treatment; NSG xenograft orthotopic tumor model; RNA-sequencing on PAPPA-KO vs. control EWS clones\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with RNA-seq and in vivo xenograft model, multiple orthogonal readouts in single rigorous study\",\n      \"pmids\": [\"30698726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PAPPA regulates maternal adipose tissue remodeling in pregnancy through IGF bioavailability; recombinant PAPPA stimulates ex vivo human adipose tissue expansion in an IGFBP-5- and IGF-1-dependent manner; Pappa-KO mice show impaired adipose remodeling, pregnancy-induced insulin resistance, and hepatic steatosis, phenocopying aspects of gestational diabetes.\",\n      \"method\": \"Pappa knockout mouse model; ex vivo human adipose tissue expansion assay with recombinant PAPPA; IGFBP-5 and IGF-1R neutralization to confirm pathway dependence; clinical cohort correlation\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with multiple metabolic phenotypes plus ex vivo mechanistic assay with pathway-specific inhibitors, single study with orthogonal methods\",\n      \"pmids\": [\"33239385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PAPP-A transcription in polycystic kidney disease (ADPKD) is regulated through the cAMP/CREB/CBP/p300 pathway; PAPP-A deficiency inhibits cyst development in Pkd1RC/RC mice; treatment with an anti-PAPP-A monoclonal antibody blocking IGFBP4 proteolysis ameliorates cystic disease in vivo and ex vivo in embryonic kidneys, establishing PAPP-A/IGF-1 signaling as a driver of cyst growth.\",\n      \"method\": \"Pappa knockout in Pkd1RC/RC mouse model; cAMP/CREB pathway inhibitor experiments; monoclonal antibody treatment (mAb targeting IGFBP4-proteolysis exosite) in vivo and in embryonic kidney cultures; histopathology\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological antibody approach with defined mechanism, multiple in vivo and ex vivo readouts in single lab\",\n      \"pmids\": [\"31990681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PAPP-A decreases expression of ABCA1, ABCG1, and SR-B1 and reduces cholesterol efflux in THP-1 macrophage-derived foam cells by activating the IGF-1/PI3K/Akt signaling pathway, which downregulates LXRα; PI3K inhibitors or IGF-1R siRNA (but not MAPK inhibitors) rescued the effect.\",\n      \"method\": \"PAPP-A protein treatment of THP-1 macrophage-derived foam cells; PI3K inhibitors; IGF-1R siRNA knockdown; LXRα agonist rescue experiment; RT-PCR and Western blot for ABCA1/ABCG1/SR-B1/LXRα; cholesterol efflux assay\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors and siRNA with orthogonal endpoints in a single lab study\",\n      \"pmids\": [\"22503545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PAPP-A expression and secretion are strongly upregulated during in vitro differentiation of villous cytotrophoblasts into syncytiotrophoblasts (~19-fold increase in mRNA, ~8-fold increase in secretion), independent of gestational age.\",\n      \"method\": \"Primary human villous cytotrophoblast culture; real-time PCR; immunocytochemistry; TRACE immunoassay for secreted PAPP-A\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct functional localization and expression linked to trophoblast differentiation, single lab study\",\n      \"pmids\": [\"12744930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PPARγ activation inhibits PAPP-A gene expression and secretion in invasive extravillous cytotrophoblasts (EVCT) but not in villous cytotrophoblasts (VCT); since PPARγ agonist inhibits EVCT invasion, PPARγ-mediated downregulation of PAPP-A may reduce bioactive IGF-II and thereby decrease trophoblast invasion.\",\n      \"method\": \"Primary EVCT and VCT cultures isolated from first-trimester chorionic villi; PPARγ agonist treatment; PAPP-A gene expression (RT-PCR) and secretion assay\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct pharmacological intervention with transcriptional and secretion readouts, single lab, mechanistic link to invasion proposed but not directly tested\",\n      \"pmids\": [\"16388849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PAPP-A-deficient mice show resistance to indicators of diabetic nephropathy (Bowman's capsule thickening, increased glomerular size, mesangial expansion, macrophage infiltration) despite equivalent hyperglycemia compared with wild-type diabetic mice, establishing a pathogenic role of PAPP-A in diabetic kidney disease.\",\n      \"method\": \"Pappa KO mouse; streptozotocin-induced diabetes; renal histopathology; immunohistochemistry for macrophage markers\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean genetic KO with defined histological phenotype, single lab\",\n      \"pmids\": [\"23881937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In PAPP-A KO mice, mTORC1 activity is diminished and MGMT and NDRG1 (DNA repair proteins) are upregulated via post-transcriptional mechanisms; this upregulation is linked to alterations in the CCR4-NOT complex downstream of mTORC1, connecting PAPP-A deficiency to enhanced DNA damage repair and longevity.\",\n      \"method\": \"PAPP-A KO mouse; mTORC1 activity assay; Western blot for MGMT and NDRG1; CCR4-NOT complex analysis; post-transcriptional regulation assays\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic KO with pathway analysis and post-transcriptional mechanism, single lab, compared across three long-lived mutant models\",\n      \"pmids\": [\"27618784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The common SNP rs7020782 (serine variant) in PAPPA encodes a PAPP-A protein with significantly reduced proteolytic cleavage of IGFBP-4 compared to the tyrosine variant; no differences were found in cell-surface binding, complex formation with STC2 or proMBP, or STC1 inhibition, localizing the functional impact to IGFBP-4 proteolytic activity specifically.\",\n      \"method\": \"Recombinant PAPP-A variants expressed in HEK293T cells; IGFBP-4, IGFBP-2, IGFBP-5 cleavage assays; cell-surface binding assay; co-immunoprecipitation with STC2 and proMBP\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — in vitro recombinant protein assay with multiple substrates and controls, single lab\",\n      \"pmids\": [\"31519945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PAPP-A inhibition (neutralizing antibody) reduces IGF signaling and ECM gene expression system-wide in adult mice; mesenchymal stromal cells (MSCs) in bone marrow are identified as the primary source of PAPP-A and the primary responders, with reduced MSC number and IGF signaling accounting for decreased bone, marrow adiposity, and myelopoiesis; MSC-like cells are also the major PAPP-A source in other tissues.\",\n      \"method\": \"PAPP-A neutralizing antibody treatment in adult mice; transcriptomic profiling across tissues; bone marrow fractionation; immunohistochemistry; IGF signaling assays\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological antibody with transcriptomic and cell-type-specific mechanistic readouts, single lab\",\n      \"pmids\": [\"33561324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PAPP-A activates the collagen receptor DDR2 and promotes metastasis in post-partum mammary glands; CRISPR deletion of DDR2 abolished the pro-invasive effect of PAPP-A, establishing DDR2 as a required downstream effector; PAPP-A also converts anti-proliferative post-partum collagen into pro-tumorigenic collagen architecture.\",\n      \"method\": \"PAPP-A transgenic/KO mouse model; second-harmonic generation microscopy for collagen architecture; CRISPR/Cas9 DDR2 knockout; invasion assay; transcriptomic analysis\",\n      \"journal\": \"Breast cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR epistasis with invasion assay and structural collagen analysis, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"31046834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In human lung fibroblasts (NHLF), TGF-β treatment increases PAPP-A levels and proteolytic activity in conditioned medium ~4-fold and stimulates IGF-I expression; the resulting PI3K/Akt signaling is significantly inhibited by both IGF-I-inactivating and PAPP-A inhibitory antibodies; senescent NHLF secrete 10-fold more PAPP-A with increased proteolytic activity, and active PAPP-A is also present on secreted extracellular vesicles.\",\n      \"method\": \"Primary NHLF cultures; TGF-β treatment; PAPP-A activity assay; PI3K/Akt phosphorylation assay; IGF-I and PAPP-A inhibitory antibodies; senescence induction; extracellular vesicle isolation and characterization\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (activity assay, signaling, EV characterization) with pathway-specific inhibitors in primary human cells, single lab\",\n      \"pmids\": [\"35098542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In human ovarian carcinoma ascites, PAPP-A (present at 46-fold higher concentration than in serum) is predominantly enzymatically active and drives IGFBP-4 cleavage; ascites has greater IGF-IR-activating potency than serum, and addition of recombinant PAPP-A to ascites further increased IGFBP-4 cleavage and IGF-IR activation, establishing PAPP-A proteolytic activity as the mechanism enhancing IGF bioactivity in ovarian cancer.\",\n      \"method\": \"IGFBP-4 cleavage assay in ascites; IGF-IR activation bioassay; immunohistochemistry on tumor tissue; addition of recombinant PAPP-A ex vivo\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ex vivo functional assay on human clinical samples with recombinant PAPP-A addition, single lab\",\n      \"pmids\": [\"26336825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Human adipose tissue cultures secrete enzymatically active PAPP-A in a depot-specific manner: visceral adipose tissue (VAT) secretes ~4-fold more PAPP-A and generates more PAPP-A-cleaved IGFBP-4 fragments than subcutaneous adipose tissue (SAT), with correspondingly greater IGF-IR-activating potency in VAT conditioned medium.\",\n      \"method\": \"Human adipose tissue explant cultures (VAT and SAT); PAPP-A ELISA; intact and cleaved IGFBP-4 fragment immunoassays; IGF-IR activation bioassay\",\n      \"journal\": \"European journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct measurement of enzymatic activity and downstream IGF-IR activation from depot-specific primary human tissue cultures, single lab\",\n      \"pmids\": [\"27585595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In human mesangial cells, IL-1β is the most potent stimulator of PAPP-A expression (~5-fold) followed by TNF-α (~2.5-fold); PAPP-A produced is secreted, cell-associated, and proteolytically active; IGF-1 complexed to wild-type but not protease-resistant IGFBP-4 stimulates mesangial cell proliferation, establishing that PAPP-A-mediated IGFBP-4 cleavage is required to release IGF-1 for mitogenic signaling in these cells.\",\n      \"method\": \"Primary human mesangial cell cultures; cytokine treatment; PAPP-A ELISA and activity assay; [3H]-thymidine incorporation proliferation assay with wild-type vs. protease-resistant IGFBP-4\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity measurement, protease-resistant IGFBP-4 as mechanistic control, functional proliferation assay; single lab\",\n      \"pmids\": [\"27519211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CRP and TNF-α induce PAPP-A mRNA and protein expression in human peripheral blood mononuclear cells (PBMCs) in a dose- and time-dependent manner; this induction is mediated through the NF-κB pathway, as demonstrated by actinomycin D and NF-κB inhibitor (BAY11-7082) experiments.\",\n      \"method\": \"Human PBMC cultures; CRP and TNF-α stimulation; RT-PCR, Western blot, ELISA; actinomycin D (transcription inhibitor); NF-κB inhibitor BAY11-7082\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — transcriptional and translational evidence with pathway inhibitor validation, single lab\",\n      \"pmids\": [\"22997483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PAPP-A expression in human primary omental preadipocytes is preferentially elevated compared to mesenteric and subcutaneous preadipocytes; TNF-α and IL-1β upregulate PAPP-A expression via the NF-κB and JNK/p38 MAPK pathways; resveratrol downregulates PAPP-A expression under basal and stimulated conditions through SIRT1/AMPK-independent pathways.\",\n      \"method\": \"Primary human preadipocyte cultures from omental, mesenteric, and subcutaneous depots; cytokine treatment; pathway inhibitors; resveratrol treatment; qRT-PCR and protein assays\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — depot-specific primary human cells with pharmacological pathway dissection, single lab\",\n      \"pmids\": [\"24781252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Heparin induces release of PAPP-A from normal arterial wall tissue (but not from non-arterial tissue or from atherosclerotic vulnerable plaques), suggesting that elevated circulating PAPP-A in acute coronary syndrome patients is due to heparin-mediated detachment from the arterial wall rather than secretion from vulnerable plaques.\",\n      \"method\": \"Immunohistochemistry on vulnerable plaques and control tissues; ex vivo heparin incubation of arterial vs. non-arterial tissue; PAPP-A measurement in volunteers receiving heparin\",\n      \"journal\": \"Clinical biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — negative finding for plaque localization combined with positive ex vivo tissue elution experiment, mechanistically informative\",\n      \"pmids\": [\"21185276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Genetic or pharmacological (mAb-PA 1/41) inhibition of PAPP-A selectively reduces adipocyte size in visceral adipose tissue (VAT: mesenteric and pericardial) but not in subcutaneous adipose tissue (SAT) in mice on high-fat diet; in mesenteric fat, PAPP-A inhibition increased cell number (hyperplasia) alongside reduced hypertrophy, decreased macrophage marker (F4/80) and IL-6 expression, and increased adiponectin.\",\n      \"method\": \"Conditional PAPP-A gene knockdown in adult mice; anti-PAPP-A immunoneutralizing mAb (mAb-PA 1/41) in vivo; histology and adipocyte sizing; gene expression analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent approaches (genetic KD and pharmacological antibody) yielding concordant depot-selective phenotype with molecular mechanistic readouts\",\n      \"pmids\": [\"32888014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Sirtuin deficiency (any of SIRT1–SIRT7) drives chromatin rewiring via altered topologically associated domain (TAD) interactions and de novo enhancer-promoter loop formation, converging on aberrant transcriptional activation of the PAPPA gene; PAPPA mediates the pro-senescence effects downstream of sirtuin deficiency in human stem cells.\",\n      \"method\": \"Isogeneic human stem cell lines with SIRT1–SIRT7 knockouts; large-scale epigenomic analyses (Hi-C, ChIP-seq); 3D chromatin contact mapping; PAPPA knockdown in sirtuin-deficient cells; cellular senescence assays\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epigenomic and genetic approaches with functional senescence readout, single lab, novel regulatory mechanism\",\n      \"pmids\": [\"38484732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The PAPPA gene was mapped to chromosomal region 9q33.1 by fluorescence in situ hybridization (FISH) using a 3.7-kb partial PAPPA cDNA probe on both mitotic and meiotic chromosomes.\",\n      \"method\": \"Fluorescence in situ hybridization (FISH) on mitotic and meiotic chromosomes\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct chromosomal mapping by FISH, foundational genomic localization widely cited\",\n      \"pmids\": [\"7679961\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PAPP-A (pappalysin-1) is a cell surface-associated zinc metzincin metalloproteinase that cleaves inhibitory IGF binding proteins (principally IGFBP-4, but also IGFBP-2 and IGFBP-5) in an IGF-dependent manner, thereby releasing bioactive IGF in the pericellular environment for IGF receptor activation; its proteolytic activity is endogenously inhibited by stanniocalcin-2 (STC2) via a covalent 2:2 complex in which STC2 sterically occludes IGFBP-4 substrate binding (established by cryo-EM structure), and PAPP-A also possesses at least one IGF-independent, non-proteolytic biological function revealed in zebrafish; transcriptional regulation of PAPPA occurs through inflammatory cytokines (via NF-κB), PPARγ, cAMP/CREB, and sirtuin-dependent chromatin rewiring, placing PAPP-A as a locally acting amplifier of IGF signaling with roles in fetal growth, ovarian steroidogenesis, adipose tissue remodeling, kidney homeostasis, bone marrow MSC maintenance, and cancer progression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PAPP-A (pappalysin-1) is a cell surface-associated metzincin metalloproteinase that locally amplifies insulin-like growth factor (IGF) signaling by cleaving inhibitory IGF binding proteins in an IGF-dependent manner, principally IGFBP-4 but also IGFBP-2 and IGFBP-5, thereby liberating bioactive IGF for IGF receptor activation in the pericellular space [#0, #3]. Tight binding to cell-surface glycosaminoglycans positions PAPP-A to act locally on its substrates [#3]. Structural work resolved how substrate engagement and inhibition occur: PAPP-A is a flexible trans-dimer whose central domain mediates both IGFBP recognition and trans-dimerization, with IGFBP5 captured via a 25-residue anchor peptide reaching into the active site; trans-dimer formation is required for efficient IGFBP-4 but not IGFBP-5 proteolysis [#7]. Its proteolytic activity is endogenously suppressed by stanniocalcin-2 through a covalent 2:2 complex in which STC2 forms an intermolecular disulfide and sterically excludes IGFBP-4 from the substrate-binding region while leaving the catalytic site accessible to peptides [#6]. Through this IGF-releasing activity PAPP-A acts as a local effector across tissues: it is required for ovarian steroidogenesis and female fertility [#4], maternal adipose remodeling in pregnancy [#10], and drives pathology in diabetic nephropathy, polycystic kidney disease, and multiple cancers via IGF-1R/PI3K/Akt signaling [#11, #12, #21]. Inhibitory monoclonal antibodies targeting the IGFBP-4-cleavage exosite suppress AKT signaling and tumor growth, establishing the proteolytic function as therapeutically tractable [#5, #11]. PAPP-A transcription is induced by inflammatory cytokines via NF-\\u03baB, repressed by PPAR\\u03b3, and activated by cAMP/CREB and by sirtuin-deficiency-driven chromatin rewiring linked to senescence [#24, #14, #11, #28]. Beyond its protease function, PAPP-A also possesses at least one IGF-independent biological activity, demonstrated in zebrafish where a catalytically dead protein rescues a developmental phenotype [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 1979,\n      \"claim\": \"Before any enzymatic role was known, the first question was simply what kind of protein PAPP-A is; early purification defined it as a large, acidic glycoprotein and tentatively assigned in vitro effects on coagulation and complement.\",\n      \"evidence\": \"Protein purification and in vitro complement/plasmin/coagulation inhibition assays\",\n      \"pmids\": [\"518134\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The coagulation/complement activities were not corroborated by later mechanistic work\", \"No catalytic or substrate identity established at this stage\"]\n    },\n    {\n      \"year\": 1983,\n      \"claim\": \"Refining the early biochemical picture, the anticoagulant effect was shown to act indirectly via antithrombin III activation and to depend on strongly acidic (heparin-like) residues, hinting at the charged surface properties later relevant to glycosaminoglycan binding.\",\n      \"evidence\": \"In vitro coagulation assay with antithrombin III titration and protamine sulfate neutralization\",\n      \"pmids\": [\"6197764\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of anticoagulant activity unestablished\", \"No connection to a catalytic mechanism\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Genomic localization was needed to enable molecular study; FISH mapped PAPPA to 9q33.1.\",\n      \"evidence\": \"Fluorescence in situ hybridization on mitotic and meiotic chromosomes\",\n      \"pmids\": [\"7679961\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mapping alone provides no functional information\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The defining mechanistic breakthrough resolved what PAPP-A actually does: it is the long-sought IGF-dependent IGFBP-4 protease, cleaving IGFBP-4 only when IGF is bound and thereby releasing bioactive IGF.\",\n      \"evidence\": \"Biochemical purification and protease activity assay from human fibroblast conditioned media\",\n      \"pmids\": [\"17218136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define catalytic mechanism or structural basis of IGF dependence\", \"Full substrate repertoire not yet established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Synthesizing across studies established PAPP-A as a metzincin metalloproteinase that cleaves IGFBP-4/-2/-5 and binds cell-surface glycosaminoglycans, positioning it as a local amplifier of pericellular IGF signaling.\",\n      \"evidence\": \"Review integrating biochemical assays, cell-surface binding experiments, and knockout mouse data\",\n      \"pmids\": [\"17218136\", \"25617049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of cell-surface tethering not resolved\", \"How catalysis is regulated in vivo unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"To test physiological necessity of the protease activity, knockout mice showed loss of ovarian IGFBP-4 proteolysis causes reduced ovulation, lowered steroid hormones, and impaired fertility, establishing an in vivo reproductive role.\",\n      \"evidence\": \"Pappa knockout mouse with follicular IGFBP-4 activity assay, serum hormone, and ovarian gene expression\",\n      \"pmids\": [\"20130263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate proteolytic from non-proteolytic contributions\", \"Upstream regulation of ovarian PAPP-A not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A pivotal question was whether PAPP-A function is solely proteolytic; rescue of a zebrafish developmental phenotype by catalytically dead protein demonstrated a biologically important IGF-independent, non-proteolytic function.\",\n      \"evidence\": \"Zebrafish morpholino knockdown rescued by wild-type vs. active-site-mutant papp-a mRNA\",\n      \"pmids\": [\"23430244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the non-proteolytic function unknown\", \"No partner or pathway for this activity identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"To establish therapeutic tractability and confirm that IGFBP-4 cleavage drives pericellular IGF signaling, an exosite-targeting inhibitory antibody suppressed AKT signaling and tumor growth.\",\n      \"evidence\": \"Inhibitory mAb (Ki=135 pM), AKT phosphorylation assay, and A549 xenograft model\",\n      \"pmids\": [\"24572990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tested in a single tumor model\", \"Did not address resistance or systemic effects\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The structural basis of endogenous inhibition and substrate recognition was resolved: STC2 inhibits PAPP-A by covalent disulfide locking and steric substrate exclusion, while a separate structure showed PAPP-A as a trans-dimer engaging IGFBP via an anchor peptide reaching the active site.\",\n      \"evidence\": \"Single-particle cryo-EM of the 2:2 PAPP-A\\u00b7STC2 complex and of inactive PAPP-A(E483A) with an IGFBP5 peptide, plus mutagenesis and cleavage assays\",\n      \"pmids\": [\"36257932\", \"36127359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures cover N-terminal/central regions; full-length conformational dynamics incomplete\", \"Structural basis of cell-surface and glycosaminoglycan binding not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Recurring questions about tissue-specific roles were addressed by knockout and antibody studies showing PAPP-A drives cyst growth in polycystic kidney disease, maternal adipose remodeling, and depot-selective visceral adiposity through IGF bioavailability.\",\n      \"evidence\": \"Pappa KO and anti-PAPP-A mAb in Pkd1 and high-fat-diet mouse models, ex vivo human adipose assays with pathway-specific neutralization\",\n      \"pmids\": [\"31990681\", \"33239385\", \"32888014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of depot selectivity not fully resolved\", \"Whether non-proteolytic function contributes to these phenotypes untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"In cancer, CRISPR and antibody studies established PAPP-A as essential for tumor cell survival and metastasis, acting via local IGF-1 bioavailability and, in mammary metastasis, the collagen receptor DDR2.\",\n      \"evidence\": \"CRISPR knockout, RNA-seq, and xenograft in Ewing sarcoma; DDR2 CRISPR epistasis and collagen imaging in mammary models\",\n      \"pmids\": [\"30698726\", \"31046834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link between PAPP-A protease activity and DDR2 activation not mechanistically resolved\", \"Interferon/immune-evasion connection in EWS correlative\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Transcriptional control of PAPPA was progressively mapped to inflammatory cytokine/NF-\\u03baB and JNK/p38 signaling, PPAR\\u03b3 repression, cAMP/CREB activation, and sirtuin-deficiency-driven chromatin rewiring that converges on PAPPA to mediate senescence.\",\n      \"evidence\": \"Cytokine and pathway-inhibitor studies in PBMCs, mesangial cells, and preadipocytes; PPAR\\u03b3 agonist in trophoblasts; Hi-C/ChIP-seq with PAPPA knockdown in sirtuin-KO stem cells\",\n      \"pmids\": [\"22997483\", \"27519211\", \"24781252\", \"16388849\", \"38484732\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PAPPA promoter/enhancer elements not fully defined\", \"Integration of these regulatory inputs in vivo unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity and partners of the IGF-independent, non-proteolytic PAPP-A function remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No effector or pathway identified for the non-proteolytic activity\", \"Whether it operates in mammalian tissues is untested\", \"No structural correlate of a non-catalytic function\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 5, 6, 7]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 3, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [13, 21, 22, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 12, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 15, 19, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 8, 10, 13]}\n    ],\n    \"complexes\": [\"PAPP-A\\u00b7STC2 2:2 inhibitory complex\", \"PAPP-A trans-dimer\"],\n    \"partners\": [\"IGFBP4\", \"IGFBP5\", \"IGFBP2\", \"STC2\", \"IGF1\", \"DDR2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}